SARS Vaccine Protective in Mice by Stadler, Konrad et al.
LETTERS
Subsequently, we determined in a
blinded setting the presence of LGV in
a selected group of patients (clinical
spectrum and epidemiology described
elsewhere [8]) according to C. tra-
chomatis–positive rectal swab
(Chlamydia 2SP Collection &
Transport Kit [Quelab] by commer-
cially available PCR (COBAS
AMPLICOR, Hoffman-La Roche
Ltd). By using the 2 reference stan-
dard techniques to type C. trachomatis
serovars (PCR-based RFLP of the
omp1 gene or sequencing the variable
segment 2 [VS-2] of the omp1 gene)
(9,10) with DNA isolated from rectal
swab specimens (standard isopropanol
DNA isolation method), we identified
28 of 125 men as LGV-positive. These
28 samples were also positive in both
the TaqMan and Rotorgene assays. We
also identified 2 additional LGVinfec-
tions, which were initially typed and
then retested as single-strain infections
with serovars E and D by both PCR-
based RFLP analysis and VS-2
sequencing. This discrepancy is most
likely due to a double infection, which
will, in most cases, result in the prefer-
ential amplification of 1 strain in the
omp1 PCR and PCR-based sequenc-
ing methods; in the TaqMan and
Rotorgene assays, only LGV strains
can be amplified. Whether this out-
break is partially technically driven
must be assessed in the future by retro-
spectively investigating the presence
of these LGV infections in men who
have sex with men and the presence of
the L2b strain in the past, since at pres-
ent only LGV infections from 2003 to
2005 have been investigated.
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SARS Vaccine
Protective in Mice 
To the Editor: Less than a year
after the identification of the severe
acute respiratory syndrome coron-
avirus (SARS-CoV) (1), 3 independ-
ent laboratories reported protection
from SARS-CoV challenge in animal
models using a DNA vaccine or
recombinant forms of the modified
vaccinia Ankara or a parainfluenza
virus, encoding the spike gene (2–4).
Their protective efficacies are encour-
aging because they provide proof that
a SARS-CoV vaccine is feasible.
However, vaccines based on those
technologies are not licensed for
human use, and recommendation and
licensing will likely take many years.
We have developed an inactivated
virus vaccine that induces neutraliz-
ing antibodies and protects against
SARS-CoV challenge.
The vaccine was produced as
described elsewhere (5). Briefly, the
SARS-CoV (strain FRA, GenBank
accession no. AY310120) was grown
in Vero cells, inactivated with β-pro-
piolactone (BPL), and complete inac-
tivation was confirmed by 2 consecu-
tive passages on Vero cells.
Inactivated virus was purified by col-
umn chromatography followed by
sucrose gradient centrifugation. The
fraction containing virus was dialyzed
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against phosphate-buffered saline pH
7.2, and total protein content was
determined by using the Micro BCA
Protein Assay Kit (Pierce
Biotechnology, Rockford, IL, USA).
Immunogenicity of the vaccine was
tested by immunizing BALB/c mice
at 0, 2, and 4 weeks with 5 µg of inac-
tivated virus combined with the adju-
vant MF59, an oil squalene-in-water
emulsion (6) approved for human use
in Europe for an influenza vaccine.
Ten days after the third immunization,
serum samples were tested for the
presence of SARS-CoV spike pro-
tein–specific antibodies by using
enzyme-linked immunosorbent assay,
and high titers (1–3 × 104) of anti-
SARS-CoV spike immunoglobulin
(Ig) G antibodies were detected. IgG
subclass determination indicated a
predominant Th2-type immune
response similar to that observed in
BALB/c mice vaccinated with a UV-
inactivated SARS-CoV plus alum (7).
Efficacy of the inactivated virus
vaccine was also assessed in a
BALB/c mouse model of SARS-CoV
infection (8). Animal studies were
approved by the National Institutes of
Health Animal Care and Use
Committee and were conducted in an
animal biosafety level 3 facility.
SARS-CoV replicates in the respira-
tory tract of BALB/c mice following
intranasal infection with 104 50% tis-
sue culture infectious doses (TCID50)
of virus. Generally, virus titers peak
within 2 days after infection and are
cleared within 7 days (8). BALB/c
mice were immunized at 0, 2, and 4
weeks with 5 µg of BPL-inactivated
SARS virus with or without the MF59
adjuvant. Mice were also immunized
with 4 different control preparations:
phosphate-buffered saline, adjuvant
MF59 alone, and 5 µg of BPL inacti-
vated influenza A virus vaccine with
or without MF59. Serum samples
were collected 2 weeks after each
dose, and assayed for their ability to
neutralize SARS-CoV (8). After 2
vaccine doses, SARS-CoV neutraliz-
ing antibodies were detected only in
the group of mice immunized with the
BPL-inactivated SARS virus vaccine
plus MF59 adjuvant (1:91). Two
weeks after the third dose, the BPL-
inactivated SARS virus vaccine with-
out MF59 induced neutralizing titers
of 1:64, while the adjuvanted vaccine
elicited neutralizing titers >1:600
(Table).
Mice were challenged intranasally
at this point with 104 TCID50 SARS-
CoV (Urbani strain, GenBank acces-
sion no. AY278741). Nasal turbinates
and lung tissues were analyzed for
infectious virus 2 days later (Table).
SARS-CoV titers in mice from the
control groups were ≈106 TCID50
virus/g of lung tissue and ≈103
TCID50 virus/g of nasal turbinate tis-
sue. Complete protection from virus
replication was observed in mice that
received the MF59 adjuvanted SARS-
CoV vaccine. Immunization with the
nonadjuvanted vaccine resulted in
complete protection of the upper res-
piratory tract and a significant reduc-
tion (30,000-fold) of viral titers in the
lower respiratory tract compared to
the control groups. The incomplete
protection of this group was attributed
to a single animal that contained
detectable infectious virus in the lung. 
Accelerated or enhanced virus
replication or disease in immunized
persons is a concern in developing
any vaccine. This may be particularly
true for SARS-CoV vaccines since
adverse effects have been reported
for one animal coronavirus vaccine,
feline infectious peritonitis virus (9).
Additionally, some in vitro experi-
ments were performed with pseudo-
typed lentiviruses that expressed the
spike glycoprotein derived from
SARS-like virus isolated from civets.
In these experiments, the presence of
antibodies that neutralized most
human isolates of SARS-CoV
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demonstrated enhanced entry into
renal epithelial cells (10). In our stud-
ies, we did not find enhanced virus
replication in the respiratory tract of
vaccinated mice upon SARS-CoV
challenge. However, since mice are a
model of SARS-CoV infection but
not disease, the issue of disease
enhancement will have to be careful-
ly evaluated if and when an appropri-
ate animal model in which this phe-
nomenon can be demonstrated
becomes available.
In summary, an inactivated SARS-
CoV vaccine, produced with a tech-
nology that has a safety record estab-
lished by immunizing hundreds of
millions of persons, protects mice
from challenge with SARS-CoV. The
vaccine adjuvanted with MF59 elicits
neutralizing antibodies (titer 1:91)
after only 2 doses. We conclude that
the vaccine described here has desir-
able properties, and our data support
further development and plans for
clinical trials.
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Echinococcosis,
Ningxia, China 
To the Editor: Ningxia is the
smallest provincial autonomous
region on the Loess Plateau in central
China, with a population of ≈5.5 mil-
lion persons composed of 35 ethnic
and various religious groups. The nat-
ural environmental conditions and
socioreligious ethnic status in
Ningxia, particularly the southern
region, are conducive to sheep farm-
ing, an important part of the agricul-
tural economy. Both cystic echinococ-
cosis (CE) and alveolar echinococco-
sis (AE) (1) are endemic in the north-
west part of China; high prevalences
have been reported in several
provinces (1), including Gansu (2,3)
and the Xinjiang Uigur Autonomous
Region (4). Little information is avail-
able about the extent of human
echinococcosis in Ningxia; this is the
first report of a provincial investiga-
tion for both human CE and AE there.
We conducted a retrospective sur-
vey of clinical records from 7 local
county hospitals and 4 other hospitals
in Yinchuan to determine the epidemi-
ology of human echinococcosis in
southern Ningxia. All surgical and
clinical records were checked, and
diagnoses were confirmed based on
imaging, surgical reports, and
histopathologic reports. Data concern-
ing age, sex, domicile, ethnicity, occu-
pation, year of diagnosis, cyst or
lesion numbers and anatomical loca-
tion, type and duration of
anthelminthic treatment (if given),
and the nature and number of surger-
ies performed for echinococcosis
were recorded for each confirmed CE
and AE patient.
From 1985 to 2002, a total of
2,216 cases of echinococcosis were
recorded, most of which were due to
CE (96%). The incidence of com-
bined CE and AE from 1994 to 2001
was 7/100,000 persons for southern
Ningxia, compared with 1/100,000
persons for Yinchuan in the north
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